COMPARISON
Dulaglutide vs Exenatide
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Dulaglutide is authorised or registered in 10 and Exenatide in 5 of the 10 registers read. Dulaglutide: highest phase Phase 4 (after approval). Exenatide: highest phase Phase 2. 15 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Dulaglutide | Exenatide | |
|---|---|---|
| Registered trials differs | 144 clinicaltrials.gov · 2026-10-03 | 383 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: TRULICITY openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Byetta openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Withdrawn ema · 2026-10-03 |
| EU authorised on differs | 2014-11-21 ema · 2026-10-03 | Not checked no record of "authorisedOn" for exenatide |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for dulaglutide | 2024-11-20 ema · 2026-10-03 |
| ATC code differs | A10BJ05 ema · 2026-10-03 | A10BJ01 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Dulaglutide | placebo | Exenatide | placebo |
|---|---|---|---|---|
| Back pain | 8.4% | 7.9% | 0.5% | 0.6% |
| Constipation | 7.2% | 4.1% | 0.8% | 0.3% |
| Nausea | 14.5% | 5.5% | - | - |
| Diarrhoea | 12.8% | 8.5% | - | - |
| Nasopharyngitis | 11.2% | 10.4% | - | - |
| Urinary tract infection | 10.2% | 9.8% | - | - |
| Bronchitis | 7.9% | 8.3% | - | - |
| Hypoglycaemia | 7.5% | 6.6% | - | - |
| Arthralgia | 7.3% | 7.6% | - | - |
| Decreased appetite | 7.1% | 2.2% | - | - |
| Headache | - | - | 1.9% | 1.3% |
| Non-cardiac chest pain | - | - | 1.1% | 1.0% |
| Osteoarthritis | - | - | 0.9% | 1.0% |
| Dizziness | - | - | 0.8% | 0.4% |
| Dyspepsia | - | - | 0.8% | 0.3% |
| Chronic obstructive pulmonary disease | - | - | 0.7% | 0.7% |
| Fatigue | - | - | 0.6% | 0.1% |
| Sinusitis | - | - | 0.5% | 0.2% |
Trial register Dulaglutide: 11 placebo-controlled trials; Exenatide: 24. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Dulaglutide side effects · Exenatide side effects
LEGAL STATUS
Approval in each country read
| Country | Dulaglutide | Exenatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Withdrawn | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Not on the register | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
15 registered trials include both
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
|---|---|
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists RECRUITING · updated 2026-07-24 |
| NCT07309094 | Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD RECRUITING · updated 2025-12-30 |
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Rea ACTIVE_NOT_RECRUITING · updated 2025-09-23 |
| NCT06257966 | A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin ACTIVE_NOT_RECRUITING · updated 2025-09-17 |
| NCT03492580 | A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants COMPLETED · updated 2025-06-25 |
| NCT06449235 | Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh UNKNOWN · updated 2024-07-16 |
| NCT05136287 | SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULT COMPLETED · updated 2024-02-28 |
| NCT05161429 | BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes UNKNOWN · updated 2023-06-22 |
| NCT01511393 | An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) ENROLLING_BY_INVITATION · updated 2023-06-13 |
| NCT02787551 | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FR COMPLETED · updated 2022-03-25 |
| NCT03444142 | Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes UNKNOWN · updated 2020-03-26 |
| NCT04184947 | Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists COMPLETED · updated 2020-03-11 |
| NCT03959865 | GLP-1 REceptor Agonists and Real World EvIdeNce UNKNOWN · updated 2019-05-22 |
| NCT01064687 | A Study in Participants With Type 2 Diabetes Mellitus COMPLETED · updated 2015-01-26 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.